TWI821804B - Il-7結合蛋白及其於醫療中之用途 - Google Patents

Il-7結合蛋白及其於醫療中之用途 Download PDF

Info

Publication number
TWI821804B
TWI821804B TW110144544A TW110144544A TWI821804B TW I821804 B TWI821804 B TW I821804B TW 110144544 A TW110144544 A TW 110144544A TW 110144544 A TW110144544 A TW 110144544A TW I821804 B TWI821804 B TW I821804B
Authority
TW
Taiwan
Prior art keywords
binding protein
seq
set forth
acid sequence
amino acid
Prior art date
Application number
TW110144544A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237183A (zh
Inventor
葛班 布瑪
愛德華 湯瑪士 考斯朵克
大衛 迪森
史蒂芬妮 侯普利
艾倫 彼得 利維斯
潔西卡 琳 尼森
Original Assignee
英商葛蘭素史密斯克藍智慧財產發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商葛蘭素史密斯克藍智慧財產發展有限公司 filed Critical 英商葛蘭素史密斯克藍智慧財產發展有限公司
Publication of TW202237183A publication Critical patent/TW202237183A/zh
Application granted granted Critical
Publication of TWI821804B publication Critical patent/TWI821804B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110144544A 2020-12-02 2021-11-30 Il-7結合蛋白及其於醫療中之用途 TWI821804B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063120564P 2020-12-02 2020-12-02
US63/120,564 2020-12-02

Publications (2)

Publication Number Publication Date
TW202237183A TW202237183A (zh) 2022-10-01
TWI821804B true TWI821804B (zh) 2023-11-11

Family

ID=78844686

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110144544A TWI821804B (zh) 2020-12-02 2021-11-30 Il-7結合蛋白及其於醫療中之用途

Country Status (15)

Country Link
US (3) US11802150B2 (https=)
EP (1) EP4255928A1 (https=)
JP (1) JP2023551935A (https=)
KR (1) KR20230098288A (https=)
CN (1) CN116547002A (https=)
AR (1) AR124286A1 (https=)
AU (1) AU2021391493C1 (https=)
CA (1) CA3199648A1 (https=)
CL (1) CL2023001556A1 (https=)
CO (1) CO2023007851A2 (https=)
IL (1) IL303134A (https=)
MX (1) MX2023006294A (https=)
PH (1) PH12023551170A1 (https=)
TW (1) TWI821804B (https=)
WO (1) WO2022117526A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
US8961967B2 (en) * 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Chen et. al., "The novel role of IL-7 ligation to IL-7R in myeloid cells of rheumatoid arthritis and collagen induced arthritis" J Immunol., 190(10), NIH PA, 2013, p. 5256–5266

Also Published As

Publication number Publication date
JP2023551935A (ja) 2023-12-13
CN116547002A (zh) 2023-08-04
AU2021391493A1 (en) 2023-06-08
IL303134A (en) 2023-07-01
US11802150B2 (en) 2023-10-31
AU2021391493A9 (en) 2024-05-23
AU2021391493C1 (en) 2026-04-16
AR124286A1 (es) 2023-03-15
US20240025988A1 (en) 2024-01-25
CL2023001556A1 (es) 2023-11-10
MX2023006294A (es) 2023-06-13
KR20230098288A (ko) 2023-07-03
EP4255928A1 (en) 2023-10-11
PH12023551170A1 (en) 2024-01-22
WO2022117526A1 (en) 2022-06-09
US20240425581A1 (en) 2024-12-26
AU2021391493B2 (en) 2025-10-30
US12122828B2 (en) 2024-10-22
US20220169717A1 (en) 2022-06-02
TW202237183A (zh) 2022-10-01
CO2023007851A2 (es) 2023-06-30
CA3199648A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US12180288B2 (en) Antibodies to canine interleukin-4 receptor alpha
AU2016270640B2 (en) Anti-CD40 antibodies and uses thereof
AU2016201741B2 (en) IL-18 binding molecules
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2020504095A (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
MX2010012142A (es) Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
KR20140116525A (ko) 항cxcr3 항체
KR20170018814A (ko) Il-21에 특이적인 결합 분자 및 이들 용도
EP3816289A1 (en) Novel anti-pad2 antibody
CN117062836A (zh) 抗il1rap抗体
US20240425581A1 (en) IL-7 Binding Proteins and Their Use in Medical Therapy
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20250340653A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha i
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
TW202328191A (zh) 使用her3抗原結合分子的癌症之治療及預防
WO2023049867A1 (en) Orai1 multispecific antibodies and methods of use
TW202413441A (zh) TNF-α結合蛋白及IL-7結合蛋白於醫藥治療之用途
WO2023017149A1 (en) Thioredoxin 1 antibodies
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra